secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aardvark Therapeutics, Inc. (AARD)
CIK:        0001774857
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001193125-26-047757
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aardvark COO exits to lead new dermatology subsidiary; CFO Sun adds COO role
----------------------------------------------------------------------------

- Bryan Jones stepped down as COO of Aardvark on Feb 9, 2026, to become CEO of wholly-owned subsidiary Ardia Therapeutics.
- Ardia will develop DIA-615, a topical treatment for inflammatory skin diseases including psoriasis.
- CFO Nelson Sun appointed COO in addition to his CFO role, effective Feb 9, 2026; no compensation change.
- Derrick C. Li appointed Chief Business Officer, effective Feb 9, 2026.
- Jones received accelerated vesting of 17,797 shares and continued option exercise while at Ardia; waived severance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1774857/000119312526047757/0001193125-26-047757-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1774857/000119312526047757/ck0001774857-20260209.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-047757

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer